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NSCLC patients with known targetable molecular mutations is 
treatment of limited metastatic progression or 
oligoprogression.  This is due to the fact that most patients 
with treatable mutations in NSCLC progress in a limited 
number of metastases.  Ablation of these metastases has 
been shown to allow patients to remain on therapy longer 
thereby extending the time to the next line of therapy.  
Melanoma and Renal Cell Carcinoma, classically described 
“radioresistant” histologies, respond well to ablative 
radiation.  Ablation of all known metastases has resulted in 
high (80-90%) rates of treated tumor control.  Comparative 
analyses of metastastic melanoma patients treated with 
metastasectomy versus standard of care demonstrated 
improved survival for those treated with removal of 
metastases.  However this was prior to the advent of 
improved immunomodulatory and targeted agents for 
metastatic melanoma.  Furthermore, treatment of 
oligometastases with radiation has the potential to act as an 
immunosensitizer, stimulating the immune system and 
enhancing the response to immunomodulatory agents, 
perhaps inducing an abscopal effect.  
Evidence also shows that oligometastases are common in 
prostate cancer.  Ongoing studies are determining if ablative 
therapy to all known prostate oligometastases can delay the 
onset of androgen deprivation therapy, limiting the time, 
side effects and cost associated with treatment. 
 There are other roles for treatment of oligometastases 
beyond improvements in survival vs standard therapies.  Many 
patients are not candidates for standard therapies due to 
medical comorbidity.  Other patients, intolerant of the side 
effects of “targeted therapies”, are left with few treatment 
options.  Ablation of all metastases through surgery if 
feasible and possible or radiation can serve as another line of 
therapy to prolong disease free intervals.   
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Although the term 'oligometastasis' was coined in the 1990's, 
the first reports of treating limited metastatic disease with 
surgical resection originated six decades earlier. Several 
modalities are available to treat metastatic lesions, including 
surgical resection, stereotactic radiotherapy, conventional 
radiotherapy, and radiofrequency ablation. 
Numerous studies have reported 'better than expected' 
survival outcomes after ablation of limited metastatic 
disease, encompassing patients with varied histologic 
subtypes and metastatic locations. However, significant 
controversies remain, as it is unclear as to the extent of 
which the 'better than expected' survival is due to the 
treatments themselves, or merely due to selection of very fit 
patients with indolent-behaving tumors. The goal of this 
presentation is to review the uncertainties associated with 
the oligometastatic state, the natural history of untreated 
oligometastatic disease, current and past clinical trials, and 
future areas of research.  
 
 
 
 
 
 
 
 
 
 
Symposium with Proffered Papers: Immunotherapy and 
radiotherapy  
 
 
SP-0498   
Ablative radiation-mediated tumour control depends on 
DNA sensing and T cell responses 
Y. Fu1 
1University of Chicago, Deaprtment of Pathology, Chicago, 
USA  
 
It is thought that ablative radiotherapy (RT), used for rapid 
control tumor growth, induces genotoxic stress and mitosis 
crisis leading to prolonged dormancy of irradiated tumor at 
local and distal site in most patients. We have unexpectedly 
observed that initial reduction of tumor burden following 
ablative RT also depends largely on type I IFN for CTL.  
Targeting tumor with IFN can control tumor growth through 
initiating a coordinated innate and adaptive immune attack 
against tumor cells.  However, the mechanism for radiation-
mediated type I IFN induction remains unclear. Here, we 
demonstrated that STING, but not MYD88, was required for 
type I IFN-dependent antitumor effects of radiation. STING in 
dendritic cells (DCs) controlled radiation-mediated IFN-β 
induction and was activated by irradiated-tumor cells. The 
cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) 
mediated DCs sensing of irradiated-tumor cells. Moreover, 
STING was essential for radiation-induced adaptive immune 
responses, which relied on type I IFN signaling on DCs. 
Exogenous IFN-β treatment rescued cGAS/STING-deficient 
immune responses. Accordingly, enhancing STING signaling by 
cGAMP administration promoted antitumor efficacy of 
radiation. Our results reveal that the molecular mechanism 
of radiation-mediated antitumor immunity depends on a 
proper cytosolic DNA-sensing pathway, pointing towards a 
new understanding of radiation and host interactions. 
Furthermore, we uncover a new strategy to improve 
radiotherapy by cGAMP treatment.  RT induced IFN can also 
upregulate PD-L1 that suppress T cell-mediated damage and 
develop radiation resistance for relapse over time.  Anti-PDL-
1 antibody can greatly reduce radiation resistance leading to 
complete tumor regression.  Furthermore, our study 
challenges the rationale for current radio/chemotherapy 
strategies and highlights the importance of immune 
activation in preventing tumor relapse.   
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Cells respond to radiation. The best known pathways involve 
DNA repair and anti-apoptotic activities. These have different 
effects on the cell, its environment and the resulting immune 
response. We will discuss a new mechanism of DNA repair 
control that makes cells less responsive to radiation and DNA 
damaging chemotherapies. In addition, local radiotherapy 
can boost antibody-based triggering of immune responses to 
tumors but also makes the cells and environment more 
susceptible for CTL based therapies. This has allowed us to 
perform genome-wide screens to identify new and unknown 
factors controlling DNA repair and susceptibility to DNA 
damaging regimes in cancer therapy. We will discuss how 
